Harness Therapeutics

About:

Harness Therapeutics is a developer of a platform for physiological upregulation of proteins using targeted translation enhancers, SINEUPs.

Website: https://www.harnesstx.com/

Top Investors: Dementia Discovery Fund, SV Health Investors, Epidarex Capital, Takeda Ventures

Description:

Harness Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currently hard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. We have a particular focus on CNS and opthalmologic disorders but our platform has applications in multiple therapy areas

Total Funding Amount:

17.7M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2019-01-01

Contact Email:

info(AT)transinetx.com

Founders:

Piero Carninci, Stefano Gustincich

Number of Employees:

11-50

Last Funding Date:

2023-11-28

IPO Status:

Private

Industries:

© 2025 bioDAO.ai